Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

swissinfo.ch - swissinfo.ch - Swiss pharma industry braced for upheaval
Swiss pharma industry braced for upheaval
www.swissinfo.ch

Switzerland is currently standing at a crossroads, said Interpharma president Jörg-Michael Rupp stated at the association's annual media conference. The landscape for the pharmaceutical industry in Switzerland has fundamentally changed, and…

bloomberg.com - Vanguards of Health Care: Merck GHI Fund Rewires Pharma's Future
Vanguards of Health Care: Merck GHI Fund Rewires Pharma's Future
Bloomberg

'Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.” Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins…

globenewswire.com - Nxera Pharma - Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
GlobeNewswire

Vamorolone is approved and marketed as AGAMREE for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral…

globenewswire.com - Orion Oyj - Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
GlobeNewswire

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) Orion Corporation (Orion Pharma) announces initiation of a Phase 2 trial evaluating ODM-212…

globenewswire.com - Santhera Pharmaceuticals Holding AG - Santhera Licenses AGAMREE (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
Santhera Licenses AGAMREE (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
GlobeNewswire

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln…

thehindubusinessline.com - Sun Pharma's innovative research company SPARC cuts workforce by 40 percent
Sun Pharma's innovative research company SPARC cuts workforce by 40 percent
BusinessLine

Sun Pharma Advanced Research Company Ltd (Sparc) said it was reducing its overall workforce by 40 per cent, largely in the US. The projected number of people in the company is 246 by FY27, down from 409 people in FY24. The reduction has been…

marketbeat.com - Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia
Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia
MarketBeat

Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S NASDAQ: ASND executives highlighted topline Week 52 results from the company's Phase 2 COACH trial, which is evaluating a once-weekly combination regimen of TransCon…

newswire.ca - Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
CNW

BELFAST, Northern Ireland, Jan. 8, 2026 /CNW/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, announced today that Ricardo…

afaqs.com - afaqs! news bureau - Eli Lilly sells science, not shame, to prime India's obesity & GLP-1 market
Eli Lilly sells science, not shame, to prime India's obesity & GLP-1 market
afaqs!

When Eli Lilly took out a front-page ad in The Times of India this New Year, it wasn't selling a drug. At least not explicitly. Instead, the American pharma giant sold a reframing. Obesity, the ad suggested, should be understood through science…

themeasure.net - Eleanor Semeraro - 57% of Consumers Fatigued By Volume of Pharma TV Ads
57% of Consumers Fatigued By Volume of Pharma TV Ads
THE MEASURE

Pharmaceutical advertising has been a hot topic in 2025, driven by heightened consumer scrutiny and rapid shifts in healthcare behavior. As new treatments, GLP-1 availability and digital health platforms scale, debates around transparency, safety…

thesun.co.uk - Julia Hartley-Brewer - Latest police scandal may be final nail in coffin for trust in bobbies
Latest police scandal may be final nail in coffin for trust in bobbies
The Sun

ANOTHER day, another police ­scandal. The Met Police has revealed it hired thousands of officers and staff in the past few years without them undergoing the required background checks, including on references and criminal records. Your info…

wsj.com - Kimberley Kao - Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
Wall Street Journal

has agreed to lower the prices of medicines that certain U.S. patients pay, making it the latest pharmaceutical company to strike a pact with the Trump administration. The healthcare conglomerate said in a statement Thursday that it has reached an…

foxnews.com - Taylor Penley - Jillian Michaels exposes how America's food system has been stacked against consumers in Fox Nation special
Jillian Michaels exposes how America's food system has been stacked against consumers in Fox Nation special
Fox News

More than 170 million Americans are overweight or obese, chronic disease is exploding, and it's no accident someone is making billions off it, reality fitness guru Jillian Michaels said Thursday. 'The ultimate rebellion is taking agency. At the end…

investopedia.com - Terry Lane - What Drove the Sharp Drop in the U.S. Trade Deficit? Gold
What Drove the Sharp Drop in the U.S. Trade Deficit? Gold
Investopedia

The U.S. trade deficit fell by nearly 40% in October, hitting its lowest level since 2009. But a big increase in non-monetary gold exports, along with a steep decline in pharmaceutical chemical imports, are responsible for much of the shift. The…

globenewswire.com - eleva GmbH - Eleva appoints Erich Rajkovic as new Chief Business Officer
Eleva appoints Erich Rajkovic as new Chief Business Officer
GlobeNewswire

Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief Business Officer. Erich Rajkovic…

Receive a Daily briefing on Pharma Industry News

Get Started